Trials / Sponsors / Highlight Therapeutics
Highlight Therapeutics
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) Basal Cell Carcinoma | Phase 2 | 2024-05-27 |
| Completed | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma Melanoma | Phase 2 | 2020-12-30 |
| Terminated | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis Colorectal Cancer, Gastric Cancer, Oesophageal Cancer | Phase 2 | 2020-06-17 |
| Completed | Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors Cancer | Phase 1 | 2016-06-01 |